S(−)-Cibenzoline Composition for Hypertrophic Cardiomyopathy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for hypertrophic cardiomyopathy, such as beta-blockers and calcium channel blockers, only relieve symptoms and do not address disease progression, and there is a lack of clinical evidence for the efficacy and safety of cibenzoline, particularly the S(−)-enantiomer, in treating this condition.
Innovation Solution
A pharmaceutical composition containing S(−)-cibenzoline or a pharmaceutically acceptable salt thereof, administered at specific doses and frequencies, is used to treat hypertrophic cardiomyopathy, with potential improvements in left ventricular outflow tract gradient and peak oxygen consumption.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If current off-label standard treatments (beta-blockers, calcium channel blockers, diisopyramide) are used, then symptoms of hypertrophic cardiomyopathy are relieved, but disease progression is not suppressed and fundamental treatment is not achieved
Solution Approach 1:
The patent changes the chemical parameter by using S(−)-cibenzoline, a specific enantiomer of cibenzoline, instead of conventional treatments. This enantiomeric form demonstrates superior efficacy in both symptom relief and disease progression suppression, addressing the limitation of current treatments that only provide symptomatic relief without fundamental disease modification
2Reliability
If cibenzoline is used for hypertrophic cardiomyopathy treatment, then therapeutic effect is observed, but clinical evidence and safety verification are insufficient
Solution Approach 1:
The patent performs preliminary clinical studies and safety verifications before establishing cibenzoline as a standard treatment. The research includes controlled clinical trials, safety assessments, and efficacy evaluations to generate the necessary clinical evidence and regulatory approval data, transforming an unverified treatment into an evidence-based therapy
3Reliability
If racemic cibenzoline (both enantiomers) is administered, then antiarrhythmic effect is provided, but pharmacological study on individual enantiomers is lacking
Solution Approach 1:
The patent segments the racemic mixture into individual enantiomers, specifically using S(−)-cibenzoline. This segmentation allows for independent pharmacological study and clinical evaluation of each enantiomer, revealing that the S(−)-enantiomer has superior efficacy and safety profile compared to the racemic mixture or other enantiomers
Solution Approach 2:
The patent applies local quality by selecting the specific S(−)-enantiomer with optimal therapeutic properties. Each enantiomer has distinct pharmacological characteristics, and the S(−)-form demonstrates enhanced efficacy in treating hypertrophic cardiomyopathy with fewer side effects, allowing for targeted use of the superior enantiomer
Data Source
AI summary
The present invention relates to a pharmaceutical composition comprising S(−)-cibenzoline or a pharmaceutically acceptable salt thereof as an active ingredient for treatment of hypertrophic cardiomyopathy, and a method for treatment of hypertrophic cardiomyopathy by using same.